Morphosys AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Morphosys AG reaffirms FY 2014 guidance - Conference Call
Morphosys AG:Reconfirms financial guidance for FY 2014.Anticipates FY 2014 total growth revenues between 58 million euros and 63 million euros.Anticipates FY 2014 negative EBIT of between minus 11 million euros and minus 16 million euros.FY 2014 revenue of 62 million euros and EBIT of (16) million euros - Thomson Reuters I/B/E/S.
Latest Key Developments inBiotechnology
- Intrexon Corp and Oragenics Reports Positive In Vivo Antibiotic Efficacy Data in Critical Animal Study
- Esperion Therapeutics announces positive top-line phase 2 results for etc-1002 in patients with hypercholesterolemia and hypertension
- ESSA Pharma to commence trading on Toronto Stock Exchange
- ICON PLC raises FY 2015 EPS guidance; lowers FY 2015 revenue guidance
- Share this
- Digg this